1. Context {#sec172135}
==========

Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women ([@A33537R1]), accounting for 70% - 85% of primary liver cancers ([@A33537R2]). Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the main causes of HCC; however, only a fraction of patients with these infections will develop HCC during their lifetimes. The prevalence of HCC is correlated with the incidence of HBV and HCV in regions with a high risk of these infections, such as Asia and Africa, where HBV and HCV are the primary cause of HCC.

Tumor necrosis factor-α (TNF-α), which is associated with HCC susceptibility, is a multi-functional cytokine that helps to regulate different pathways involved in inflammation, immunity, apoptosis, anti-apoptosis, and tumorigenesis ([@A33537R3]). TNF-α was first believed to be an anti-tumor cytokine, but emerging evidence does not confirm this role. New research has identified TNF-α in a majority of cancers associated with inflammation, acting as a tumor-promoting factor. Indeed, it plays two different roles associated with cancer: it can be an endogenous tumor-promoter, or it can act as a cancer-killer ([@A33537R4]) along with activated macrophages, which are the major source of TNF-α, monocytes, lymphoid cells, and mast cells. TNF-α can also be produced by various tumor cells, including breast cancer, B-lymphoma, and colon carcinoma. Considerable research has confirmed the role of TNF-α in the promotion and progression of human cancers. It can cause activation of activator protein 1 (AP-1) and nuclear factor-kappa B (NF-κB) transcription factors through different pathways ([@A33537R5]). In some studies, TNF-α expression was elevated in HCC patients ([@A33537R6], [@A33537R7]); however, in other studies, a lower level of TNF-α was reported in HCC patients compared to healthy controls ([@A33537R8], [@A33537R9]). The critical role of TNF-α in HBV reactivation was also recently discussed by author ([@A33537R10]).

Many studies have been performed on the association between the frequency of susceptible TNF-α promoter alleles and HCC development. The most-studied polymorphism of TNF-α promoter positions in HCC development risk are -308 G/A, -238 G/A, -857 C/T, and -863 C/A.

Wilson et al. ([@A33537R11]) identified a biallelic polymorphism in the TNF-α promoter at position -308 (TNF-α-308), which was introduced as G to A transition polymorphism. The A allele is significantly less common than the G allele globally. It has been suggested that TNF-α-308 influences gene expression ([@A33537R12]). The A allele in TNF-α-308 results in a higher constitutive and inducible level of TNF expression compared to the G allele ([@A33537R13]). All of these studies indicate the importance of TNF-α-308 polymorphisms in the risk of HCC development.

2. Evidence Acquisition {#sec172140}
=======================

2.1. Publication Search {#sec172136}
-----------------------

A systematic literature search for all published articles related to HCC and TNF-α-308 polymorphisms was conducted using the databases of PubMed, Scopus, and Google Scholar. The last search update was on July 12, 2015, using the keywords "tumor necrosis factor-α" or "tumor necrosis factor-alpha" or "TNF-α", "polymorphism" or "genotype" or "SNP", and "hepatocellular carcinoma" or "HCC" or "liver cancer". The references for the selected articles were also checked for further related studies.

2.2. Selection Criteria {#sec172137}
-----------------------

The inclusion criteria were:

1\) The study design must be case-control.

2\) The outcome should be HCC.

3\) The study must include at least two groups, including a case group and a control group.

4\) The frequency of alleles and genotypes for both groups, case and control, must be given or calculated.

5\) The full article must be published in the English language.

Review articles, systematic reviews, and meta-analyses were excluded, but their references were checked for possible eligible studies based on the above criteria.

2.3. Data Extraction {#sec172138}
--------------------

The essential data were extracted from each article by both of the authors independently. All of the extracted data, including year of publication, country, study period, genotyping method, number of cases and controls, and frequency of genotypes and alleles, were categorized, then entered into our database. Any disagreement was discussed until a consensus was reached.

2.4. Statistical Analysis {#sec172139}
-------------------------

Statistical analyses were carried out using Comprehensive Meta-Analysis (CMA) software, version 2. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to measure the association between TNF-α-308 polymorphisms and the risk of HCC development. A P \< 0.05 was considered statistically significant. Heterogeneity among the studies was examined with the Cochran Q test and I^2^ statistics. When significant heterogeneity was observed (pheterogeneity \< 0.1 and I^2^ \> 50%), the random effect model was used. However, in homogeneous conditions (pheterogeneity \> 0.1 and I^2^ \< 50%), the fixed-effect model was employed. Publication bias was investigated visually with funnel plots. For calculation of overall effect size in the absence of one study, a sensitivity analysis was conducted. In this meta-analysis, both the allelic and the genotype genetics models, including per-allele (A vs. G), co-dominant (AA vs. GG), dominant (AA + AG vs. GG), and recessive models (AA vs. AG + GG), were analyzed in order to evaluate the associations between the TNF-α-308 G/A allele and HCC development risk.

3. Results {#sec172145}
==========

3.1. Publication Search {#sec172141}
-----------------------

A total of 287 articles were identified in the database search. Only articles in the English language were chosen for primary screening. After omitting 53 duplicate studies, 234 articles were considered for skimming of titles and abstracts, and 52 articles were subsequently selected for careful scanning of the context. More than half of these (29 studies) were excluded because they contained insufficient or non-relevant data for this analysis. Finally, 23 eligible studies were entered into our meta-analysis ([Figure 1](#fig32154){ref-type="fig"}). In three of these studies, the GA and AA genotypes were reported in overall form instead of separately, so they could be included only in the dominant-model analysis. [Table 1](#tbl43687){ref-type="table"} shows the summary of exported data from all of the included studies.

3.2. Association Between the TNF-α-308 G/A Polymorphism Mmodels and HCC Rrisk {#sec172142}
-----------------------------------------------------------------------------

[Figure 2](#fig32155){ref-type="fig"} indicates the association of the allelic model (A vs. G) and the risk of HCC. Overall, the A allele was identified more frequently in HCC patients than in controls (13.4% vs. 8.4%, respectively). Talaat et al. ([@A33537R14]) were the only authors to report a statistically significant difference from the overall result. In analyzing the allelic model, because of high heterogeneity (Pheterogeneity \< 0.001, I^2^ = 85%), a random effect model was used. [Figure 2](#fig32155){ref-type="fig"} shows that mutant allele A in TNF-α-308 was related to increased HCC risk (P = 0.001, OR \[95% CI\] = 1.77 \[1.26-2.50\]). For the co-dominant model (AA vs. GG), considering the significant heterogeneity among the studies (Pheterogeneity = 0.003, I^2^ = 55%), a random-effect model was employed. The analysis of the co-dominant model (P \< 0.020, OR \[95% CI\] =2.14 \[1.13-4.06\]), shown in [Figure 3](#fig32156){ref-type="fig"}, identified a possible association with HCC risk, but this result may be influenced by removing one study. Therefore, we deduced that this result was not reliable.

![Flow Chart for Identifying Potential Studies for the Meta-Analysis](hepatmon-16-04-33537-i001){#fig32154}

###### Main Characteristics of the Studies Included in the Meta-Analysis

  Study, y               Ref              Country    Study Period   Genotyping Method   Case   Control                                                                                                      
  ---------------------- ---------------- ---------- -------------- ------------------- ------ --------- ---------------------------------------- ----- ----- ---------------------------------------- ---- ----
  **Wang, 2003**         ([@A33537R15])   Japan      2000 - 2001    Direct sequencing   125    109       15                                       1     55    48                                       6    1
  **Ben-Ari, 2003**      ([@A33537R16])   Israel     NM             PCR-SSP             10     9         1^[a](#fn46740){ref-type="table-fn"}^    48    42    6^[a](#fn46740){ref-type="table-fn"}^         
  **Heneghan, 2003**     ([@A33537R17])   China      NM             PCR                 98     88        10                                       0     172   158                                      13   1
  **Ho, 2004**           ([@A33537R18])   China      2000 - 2003    PCR                 74     37        34                                       3     289   225                                      62   2
  **Niro, 2005**         ([@A33537R19])   Italy      2000 - 2003    Direct sequencing   30     24        6^[a](#fn46740){ref-type="table-fn"}^    96    75    21^[a](#fn46740){ref-type="table-fn"}^        
  **Migita, 2005**       ([@A33537R20])   Japan      2000 - 2004    PCR-SSP             48     47        1                                        0     188   183                                      5    0
  **Chen, 2005**         ([@A33537R21])   China      1997 - 2001    PCR-RFLP            572    468       95                                       9     381   311                                      67   3
  **Kummee, 2007**       ([@A33537R22])   Thailand   NM             PCR-RFLP            50     42        6                                        2     150   123                                      15   12
  **Jeng, 2007**         ([@A33537R23])   China      2001 - 2001    PCR                 108    80        28                                       0     108   100                                      8    0
  **Sakamoto, 2008**     ([@A33537R24])   Japan      2001 - 2004    PCR-RFLP            209    205       4                                        0     275   270                                      5    0
  **Jeng, 2009**         ([@A33537R25])   China      2003 - 2004    PCR                 200    149       50                                       1     200   188                                      12   0
  **Ognjanovic, 2009**   ([@A33537R26])   US         1984 - 2001    TaqMan              118    90        28^[a](#fn46740){ref-type="table-fn"}^   225   176   49^[a](#fn46740){ref-type="table-fn"}^        
  **Akkiz, 2009**        ([@A33537R27])   Turkey     2005 - 2007    PCR-RFLP            110    72        35                                       3     110   99                                       11   0
  **Wang, 2010**         ([@A33537R28])   China      NM             PCR                 230    197       30                                       3     158   143                                      15   0
  **Shi, 2011**          ([@A33537R29])   China      2007 - 2009    PCR-RFLP            88     30        43                                       15    88    45                                       35   8
  **Shi, 2012**          ([@A33537R30])   China      2000 - 2010    PCR-RFLP            73     51        20                                       2     116   84                                       30   2
  **Radwan, 2012**       ([@A33537R31])   Egypt      NM             PCR-RFLP            128    82        42                                       4     160   136                                      24   0
  **Talaat, 2012**       ([@A33537R14])   Egypt      NM             TaqMan              45     42        2                                        1     45    25                                       13   7
  **Teixeira, 2013**     ([@A33537R32])   Brazil     2001-2009      PCR                 111    81        30                                       0     202   173                                      26   3
  **Saxena, 2013**       ([@A33537R33])   India      NM             PCR-RFLP            59     52        7                                        0     139   128                                      11   0
  **Feng, 2014**         ([@A33537R34])   China      2010 - 2013    PCR                 753    611       98                                       44    760   733                                      25   2
  **Rizk, 2014**         ([@A33537R35])   Egypt      NM             PCR                 50     25        15                                       10    70    56                                       8    6
  **Sghaier, 2015**      ([@A33537R36])   Tunis      2012 - 2013    PCR-RFLP            100    25        47                                       28    200   80                                       72   48

^a^AA + GA value.

![ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the A Allele in Comparison to the G Allele (Allelic Model)](hepatmon-16-04-33537-i002){#fig32155}

![ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the AA Genotype Compared to the GG Gonotype (co-Dominant Effect)](hepatmon-16-04-33537-i003){#fig32156}

Due its significant heterogeneity (Pheterogeneity = 0.006, I^2^ = 52%), a random model was used for the recessive model ([Figure 4](#fig32157){ref-type="fig"}), showing a statistically significant association with the HCC risk (P \< 0.047, OR \[95% CI\] =1.83 \[1.01-3.33\]). However, similar to the co-dominant model, its results were not trustworthy. After analyzing the results of selected articles for the dominant model, it was noted that there was a significant association between this model in TNF-α-308 and the risk of HCC development (P \< 0.001, OR \[95% CI\] =1.80 \[1.29-2.51\]). This association is clearly shown in [Figure 5](#fig32158){ref-type="fig"}. Considering the high heterogeneity (Pheterogeneity \< 0.001, I^2^ = 81%) among the selected studies, the random model was used instead of the fixed model in the dominant model. [Table 2](#tbl43688){ref-type="table"} also summarizes the most important results for all four of the analyzed models.

![ORs and CIs of HCC risk Associated With TNF-Α-308 G/A for the AA Genotype Compared to the AG + GG Genotype (Recessive Effect)](hepatmon-16-04-33537-i004){#fig32157}

![ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the AA + AG Genotype Compared to the GG Genotype (Dominant Effect)](hepatmon-16-04-33537-i005){#fig32158}

###### Summarized Results of Pooled ORs in the Meta-Analysis

  Model                No. of Studies   Employed Model   OR \[95% CI\]        P Value    P~heterogeneity~   I^2^, %
  -------------------- ---------------- ---------------- -------------------- ---------- ------------------ ---------
  **A vs. G**          20               Random           1.77 \[1.26-2.50\]   \< 0.002   \< 0.001           85
  **AA vs. GG**        20               Random           2.14 \[1.13-4.06\]   \< 0.020   0.003              55
  **AA vs. AG + GG**   20               Random           1.83 \[1.01-3.33\]   \< 0.047   0.006              52
  **AA + AG vs. GG**   23               Random           1.80 \[1.29-2.51\]   \< 0.001   \< 0.001           81

3.3. Sensitivity Analysis {#sec172143}
-------------------------

After checking the effect of omitting any given study with a sensitivity analysis, the results of the allelic and dominant models were concluded to be completely reliable, while the other two models were considered unreliable because of alterations of the overall results in the sensitivity analysis. [Figure 6](#fig32159){ref-type="fig"} shows the sensitivity analysis results for the analyzed models.

![Results of Sensitivity Analysis for the Four Models](hepatmon-16-04-33537-i006){#fig32159}

3.4. Publication Bias {#sec172144}
---------------------

To evaluate for any evidence of publication bias among the included studies, funnel plots for all four of the models were performed ([Figure 7](#fig32160){ref-type="fig"}). The shape of these plots suggested no evidence of publication bias among the studies.

![Funnel Plot Analysis to Examine Publication Bias for all Analyzed Models](hepatmon-16-04-33537-i007){#fig32160}

4. Conclusions {#sec172146}
==============

There are several risk factors for HCC development, including cirrhosis, HBV, HCV, toxins, drinking-water contamination, and alcohol ([@A33537R37]). HCC most often develops as an outcome of HBV or HCV infections, which can be affected by various factors ([@A33537R38], [@A33537R39]). Various cytokines and cells are deeply involved in several types of diseases, such as HCC and viral hepatitis. Having a plan of their activity and functions may lead to the emergence of new therapeutic options and also better management of HBV infection ([@A33537R40], [@A33537R41]). For example, recently, Tavakolpour ([@A33537R41]) used the function of cytokines and cells to introduce a new therapeutic approach for chronic HBV. Finding the association between TNF-α polymorphisms may also lead to the emergence of some options to better management of HCC. TNF-α is also involved in HCC development ([@A33537R42], [@A33537R43]). TNF-α polymorphisms can regulate the expression of this cytokine, and different meta-analyses have shown an association between TNF-α-308 G/A and the risk of HCC ([@A33537R44]-[@A33537R47]). However, the results for TNF-238 G/A in this context have been controversial ([@A33537R44]-[@A33537R46], [@A33537R48]). Furthermore, there is limited evidence of an association between HCC and TNF-863 C/A, and no association between TNF-857 C/T or TNF-1031 T/C and the risk of HCC ([@A33537R19]). [Table 3](#tbl43689){ref-type="table"} summarizes the results of recent meta-analyses that sought to identify links between HCC risk and different positions of TNF-α promoter.

###### Summary of Previous Meta-Analysis Results for Different TNF-α Promoter Positions

  Study, y          Ref              Region        -308 G/A     -238 G/A         -857 C/T         -863 C/A     -1031 T/C
  ----------------- ---------------- ------------- ------------ ---------------- ---------------- ------------ ----------------
  **Yang, 2010**    ([@A33537R44])   Global        Associated   Not associated                                 
  **Wei, 2011**     ([@A33537R45])   Asia          Associated   Associated       Not associated   Associated   Not associated
  **Cheng, 2013**   ([@A33537R48])   Global                     Associated                                     
  **Hu, 2014**      ([@A33537R46])   Asia          Associated   Not associated                                 
  **Wang, 2014**    ([@A33537R47])   Han Chinese   Associated                                                  

The present meta-analysis investigated associations between TNF-α-308 G/A and the risk of HCC in an allelic model and all genotype models. The results for the allelic model, reflecting 20 studies, indicated a significant association with HCC risk. This is similar to the results reported by Wang et al. ([@A33537R47]), Hu et al. ([@A33537R46]), and Cheng et al. ([@A33537R48]). Due to high heterogeneity, the random model was employed for this analysis.

In addition to the A vs. G model, the AA vs. GG model was associated with HCC. However, Hu et al. ([@A33537R46]) and Cheng et al. ([@A33537R48]) did not report a relationship between this model and HCC risk. Thus, the present meta-analysis introduced an association between a co-dominant genotype model with HCC for the first time. However, a sensitivity analysis showed that these results should be considered unreliable. Thus, further studies are necessary to determine whether there is any significant association in this regard. In a recessive model, the P value was very close to 0.05, indicating statistical significance, but this was not trustworthy, as the sensitivity analysis found no association on the recessive model between HCC risk and TNF-α-308. Similar to our analysis, all of the published meta-analyses found no relationship on the recessive model.

For the dominant model, similar to all of the previously published meta-analyses, a significant association with HCC was found in the present study, confirming the previous results.

In all of the models, significant heterogeneity was observed. Thus, a random model was used for the analyses. In the allelic and dominant models, which were considered significantly associated with HCC in previous analyses, an association with HCC was also obtained in this study. However, this relationship may possibly exist in the co-dominant and recessive models. Differentiation of this result with previous studies was associated with the co-dominant model, which was not calculated in most of the other meta-analyses. Among all of the published results, Talaat's study was considerably different from the others, reporting the G allele as a risk factor for HCC. This research was carried out in Egyptian patients with chronic HCV infections. Two other studies investigated Egyptian populations, but all of them introduced the A allele as a risk factor for HCC. Our results also confirmed the A allele risk factor. In other HCV cases that developed HCC, the results were not as different as they were in this study.

A sensitivity analysis, which removes one study and repeats the analysis, may reveal that the overall results depend on a certain study or not. After the sensitivity analysis in the present study, the reliability of the final results, which showed associations between the allelic and the dominant models with HCC, was confirmed. Despite an association of the co-dominant and recessive models with HCC, based on the sensitivity analysis results, this association was not trustworthy.

The present meta-analysis may suffer from certain limitations. First, only English-language studies were included, although there are studies published in other languages, especially Chinese. Another limitation is the high heterogeneity of the data, which can cause deviations from factual results. Environmental factors and primary diseases that cause HCC should also be considered, but this was impractical with the low number of included studies. In this analysis, it was assumed that all of the enrolled studies contained accurate data; however, this may not be true. On the other hand, there were also some advantages in this analysis that previous studies lacked. For example, this meta-analysis included 23 studies, which is the highest number among similar meta-analyses. The last update of the literature search was on July 12, 2015, which is considerably more recent than the last meta-analysis. To obtain more valid and reliable results, future studies are needed.

**Authors' Contribution:**Study concept and design: Soheil Tavakolpour and Shahnaz Sali; acquisition of data: Soheil Tavakolpour; analysis and interpretation of data: Soheil Tavakolpour and Shahnaz Sali; drafting of the manuscript: Soheil Tavakolpour; critical revision of the manuscript for important intellectual content: Soheil Tavakolpour and Shahnaz Sali; statistical analysis: Soheil Tavakolpour and Shahnaz Sali; administrative, technical, and material support: Soheil Tavakolpour and Shahnaz Sali; study supervision: Soheil Tavakolpour and Shahnaz Sali.

**Financial Disclosure:**This study did not receive financial support.
